Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerström J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I; Nordic Myeloma Study Group. Lenhoff S, et al. Among authors: juliusson g. Br J Haematol. 2006 May;133(4):389-96. doi: 10.1111/j.1365-2141.2006.06042.x. Br J Haematol. 2006. PMID: 16643445 Free article. Clinical Trial.
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Osterborg A, Ahre A, Björkholm M, Björeman M, Brenning G, Gahrton G, Gyllenhammar H, Johansson B, Juliusson G, Järnmark M, et al. Osterborg A, et al. Among authors: juliusson g. Eur J Haematol. 1989 Jul;43(1):54-62. doi: 10.1111/j.1600-0609.1989.tb01252.x. Eur J Haematol. 1989. PMID: 2670605 Clinical Trial.
Low-dose cladribine for symptomatic hairy cell leukaemia.
Juliusson G, Lenkei R, Tjønnfjord G, Heldal D, Liliemark J. Juliusson G, et al. Br J Haematol. 1995 Mar;89(3):637-9. doi: 10.1111/j.1365-2141.1995.tb08377.x. Br J Haematol. 1995. PMID: 7734367 Clinical Trial.
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Karlsson K, Strömberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A, Kimby E, Lärfars G, Cristiansen I, Nilsson G, Celsing F, Sundström G, Luthman M, Tidefelt U, Wallvik J, Juliusson G. Karlsson K, et al. Among authors: juliusson g. Br J Haematol. 2002 Mar;116(3):538-48. doi: 10.1046/j.0007-1048.2001.03296.x. Br J Haematol. 2002. PMID: 11849209 Free article. Clinical Trial.
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: juliusson g. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Juliusson G, Höglund M, Karlsson K, Löfgren C, Möllgård L, Paul C, Tidefelt U, Björkholm M; Leukemia Group of Middle Sweden. Juliusson G, et al. Br J Haematol. 2003 Dec;123(5):810-8. doi: 10.1046/j.1365-2141.2003.04702.x. Br J Haematol. 2003. PMID: 14632771 Free article. Clinical Trial.
285 results